| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 159.93 | 4.0% | 14.7% |
| Total Income | 159.93 | 4.0% | 14.7% |
| Expenditure | 330.82 | 20.6% | 21.9% |
| PBT | -179.54 | 57.5% | 34.8% |
| Net Profit | -180.41 | 57.0% | 35.1% |
| OPM | — | ||
| NPM | — | ||
| EPS | -1.81 | 54.7% | 29.3% |
Ultragenyx Reports Q3 2025 Revenue of $160 Million, Up 15% YoY
04 May 2026 · 4 May, 8:11 am
Summary
Ultragenyx Pharmaceutical Inc. reported a 15% increase in total revenue for the third quarter of 2025, reaching $160 million. Crysvita revenue was $112 million, while Dojolvi revenue reached $24 million. The company reaffirmed its 2025 revenue guidance, expecting total revenue between $640 million and $670 million. Ultragenyx also announced it bolstered its balance sheet with $400 million from the sale of a portion of its Crysvita royalty interest and anticipates Phase 3 study readouts for UX143 around the end of 2025.
Key Highlights
- 1
Ultragenyx reported total revenue of $160 million for the third quarter of 2025, representing a 15% increase compared to the same period in 2024.
- 2
Crysvita revenue for Q3 2025 reached $112 million, including product sales of $47 million from Latin America and Türkiye.
- 3
Dojolvi revenue in the third quarter of 2025 amounted to $24 million.
- 4
Evkeeza revenue for Q3 2025 was $17 million as the company continues its launch in territories outside the United States.
- 5
The company reaffirmed its 2025 revenue guidance, projecting total revenue between $640 million and $670 million.
- 6
Ultragenyx bolstered its balance sheet with $400 million in proceeds from the sale of a portion of its Crysvita royalty interest.
- 7
The company expects Phase 3 study readouts for UX143 in osteogenesis imperfecta around the end of 2025.
Management Comments
Emil D. Kakkis
M.D., Ph.D.
“We are a global commercial company with multiple products generating meaningful growth that is expected to accelerate from anticipated launches from our late-stage clinical pipeline. We announced today that we bolstered our balance sheet with a royalty financing ahead of pivotal milestones expected over the next year to support multiple late-stage data readouts, multiple regulatory submissions, and multiple launches. This includes the highly anticipated phase 3 study readouts for UX143 in osteogenesis imperfecta around the end of the year.”
Informational and educational content only. Not investment advice.